Epithelial ovarian cancer (EOC) is one of the major malignant cancers with high rates of early metastasis in which regulatory T cells (Tregs) play an important role. Tregs suppress immune responses and promote the development of tumours in patients with EOC. However, the underlying mechanisms remain unclear. In this study, we found higher levels of CD4 
| INTRODUCTION
Epithelial ovarian cancer (EOC) is one of the 3 major malignant cancers among gynaecological malignancies, and it has very high rates of morbidity and mortality in females. 1 Despite ongoing efforts to develop effective surgery and treatment regimens for EOC, the overall survival rate remains a dismal 30%, which in a large part results from diagnosis at a late stage. 2 It is only once the tumour cells have spread into the peritoneal cavity that EOC can be diagnosed, which often results in a poor prognosis. 3 From previous research, ovarian cancer cells have the potential to generate different regulation mechanisms to evade anti-tumour immunity and defeat conventional tumour immunotherapy. 4, 5 The immune dysfunction in ovarian cancer patients is one of the major factors for growth and dissemination of tumours affecting disease-free survival. It is noteworthy that the host regulatory T cells (Tregs) that mediate the suppression of the immune response may be one component of immunotherapy. Various mechanisms contribute to the elevated numbers and suppressive function of Tregs in cancer. 6 Tregs are critical in the maintenance of immune tolerance and are thought to suppress efficient protective immune responses against the pathogen hindering its effective clearance. In humans, Tregs represent cells that maintain homeostasis and are defined as a subset of CD4 + T cells that express high levels of CD25 (IL-2 receptor α-chain), forkhead box P3 (FoxP3), and a low level of CD127 (alpha chain of the IL-7 receptor). 7 Tregs can inhibit tumour antigen-specific T cell responses through several mechanisms, including the release of suppressive cytokines [such as transforming growth factor-β (TGF-β), interleukin-10 (IL-10) and IL-35]. 8 Other possible mechanisms of Treg-mediated T cell suppression include IL-2 deprivation via high surface CD25 expression and release of soluble CD25. 9 Studies have reported that matrix metalloproteinases (MMPs) regulated the occurrence and development of malignant tumours by participating in cellular processes of proliferation, apoptosis and angiogenesis. 10 Gelatinases (MMP-2 and MMP-9) mainly act on denaturing and cleaving type IV collagen and gelatin. 
| MATERIALS AND METHODS

| Patients and samples
| Cell lines and culture conditions
The human EOC cell line (OVCAR3) was purchased from ATCC (Manassas, VA, USA). Cells were grown in 5% CO 2 at 37°C in RPMI 1640 (Gibco, Gaithersburg, MD, USA) containing 10% foetal bovine serum (FBS) (Invitrogen, Carlsbad, CA, USA), penicillin G (50 U/mL) and streptomycin (50 mg/mL). were seeded into the inner wells at 6 × 10 5 cells per well.
| Coculture of EOC cell line and T cells
After a 72 hours incubation period, OVCAR3 and T cells were collected separately for further analysis.
| Enzyme-linked immunosorbent assay (ELISA)
Serum sample was collected from clinical patients and healthy donors to detect the levels of IL-10 and TGF-β1.
In vitro, CD4 + CD25 high CD127 low Tregs were collected and cultured in 96-well plates with 5 × 10 4 cells per well.
Then, they were induced with soluble anti-CD3 (1 μg/mL, clone OKT3; eBioscience, San Diego, CA, USA) and anti-CD28 (1 μg/mL, clone CD28.2; eBioscience), followed by 12 and 24 hours of incubation at 37°C and 5% CO 2 .
13,14
The sorted-CD4 + CD25 high CD127 low Tregs control group was similarly stimulated. For the measurement of cytokine (IL-10 and TGF-β1) production, supernatants were removed and analysed with the ELISA Kit (eBioscience, San Diego, CA, USA). 
| Neutralizing antibodies blocking assay
| RNA isolation and RT-PCR
Total RNA was prepared and subjected to first-strand cDNA synthesis using an RNeasy Micro Kit (Qiagen, Hilden, German) and PrimeScript RT Master Mix (Takara, Shigaken, Japan). mRNA levels were measured by using SYBR Premix DimerEraser (Takara, Shigaken, Japan) in 7500 Real-time PCR detection system (Applied Biosystems/Life Technologies, Grand Island, NY, USA). Cycle threshold (CT) values were estimated by normalizing these values against β-action CT values using the 2 -▵Ct method.
| Cell invasion assay
Transwell chambers (6.5 mm) (Corning Costar, Cambridge, MA, USA) with poly-carbonate membranes (8.0 μm pores) were precoated with matrigel (Sigma, St. Louis, MO, USA). OVCAR3 cells in serum-free media were added to the upper chamber. After incubation for 16 hours, the invasive cells attached to the lower surface of the membrane insert were fixed in 4% formaldehyde and stained with 3% crystal violet. The number of invasive cells on the lower surface of the membrane was then counted in six random microscopic fields (200-fold) under an inverted microscope (Olympus, Tokyo, Japan). 
| Statistics
| High levels of IL-10 and TGF-β1 in patients with EOC
ELISA was used to detect cytokine levels in serum (Figure 1B) . The level of TGF-β1 in the EOC group (n = 34) was significantly higher than in the healthy control (n = 34) and the benign ovarian tumour group (n = 26) (103.70 ± 8.52 pg/mL vs 44.43 ± 3.68 pg/mL, P < 0.05 and 103.70 ± 8.52 pg/mL vs 49.80 ± 4.01 pg/mL, P < 0.05, respectively). The IL-10 level was also significantly higher in the EOC group (n = 34) than in the healthy control group (n = 34) and the benign ovarian tumour group (n = 26) (42.11 ± 1.91 pg/mL vs 11.09 ± 0.69 pg/mL, P < 0.05 and 42.11 ± 1.91 pg/mL vs 11.81 ± 1.02 pg/mL, P < 0.05, respectively). itive lymphatic invasion (n = 15) was significantly higher than without lymphatic invasion (n = 19) (9.70% ± 0.86% vs 7.04% ± 0.62%, P < 0.05) ( Figure 1C ). Levels of TGF-β1 and IL-10 in ovarian cancer with positive lymphatic invasion were also higher than without lymphatic high CD127 low Tregs in EOC (n = 34), benign ovarian tumour tissues (n = 26) and healthy control (n = 34) by flow cytometry.
| Significant correlations of clinicopathological variables in EOC
*P < 0.05 compared with the healthy control and benign ovarian tumour groups. B, The levels of TGF-β1 and IL-10 in EOC group (n = 34) were significantly higher than in the healthy control group (n = 34) and benign ovarian tumour group (n = 26). *P < 0.05 compared with healthy control and benign ovarian tumour groups. C, CD4 + CD25 high CD127 low Tregs, TGF-β1 and IL-10 in ovarian cancer with positive lymphatic invasion (n = 15) were significantly higher than without lymphatic invasion (n = 19). *P < 0.05 compared with negative lymphatic invasion. D, TGF-β1 and IL-10 in ovarian cancer with FIGO stage III～IV (n = 16) were significantly higher than stage I～II (n = 18). *P < 0.05 compared with stage I～II coculturing with OVCAR3. Figure 2A shows the positive expression ratio of CD127 on CD4 + CD25 high T cells.
According to Figure 2A, Figure 2C ). Tregs compared with OVCAR3 cultured alone. Inversely, mRNA levels of TIMP-2 (0.44-fold, P < 0.05) in OVCAR3 were decreased in the coculture group. However, after being pretreated with the TGF-β1 receptor or IL-10 receptor monoclonal antibodies on OVCAR3, the levels of MMP-2 significantly decreased (0.40-fold, P < 0.05 and 0.43-fold, P < 0.05, respectively), while the levels of TIMP-2 significantly increased compared to cocultured cells treated with culture medium alone (2.83-fold, P < 0.05 and 2.17-fold, P < 0.05, respectively) (Figure 3A,B) . Levels of MMP-2 and TIMP-2 were not affected when OVCAR3 was treated with the isotype IgG control or the culture medium alone.
| Expression changes of MMP-2 and TIMP-2 in EOC cells
| Invasion ability changes of EOC cells in the coculture system
The in vitro invasion effect through ECM was observed in OVCAR3 ( Figure 3C ). positive lymphatic invasion was significantly higher than without lymphatic invasion. Levels of TGF-β1 and IL-10 in ovarian cancer with positive lymphatic invasion were also higher than without lymphatic invasion. Levels of TGF-β1 and IL-10 in FIGO stage III～IV were higher in comparison with stage I～II. Other clinicopathological variables did not exhibit significant differences. *P < 0.05 TGF-β1 receptor or the IL-10 receptor monoclonal antibodies could partially remarkably weaken invasion ability of OVCAR3 (349.3 ± 25.83 vs 117.70 ± 13.91, P < 0.05 and 349.3 ± 25.83 vs 107.00 ± 9.54, P < 0.05, respectively). The invasion effect was not affected when cocultured cells were treated with the isotype IgG control or the culture medium alone.
| DISCUSSION
EOC is a common cancer in women worldwide; it accounts for 90% of the cases of ovarian cancer and is characterized by metastasis. 15 Typically, primary EOC tumours disseminate within the peritoneal cavity, primarily into the omentum. 16 Thus, it is critical to understand the contribution of genetic and environmental interactions in the development of ovarian cancer. In this occurrence, TIMPs are natural inhibitors of the MMPs, which are proteolytic enzymes involved in degradation of extracellular matrix, thereby favouring tumour cell invasion and metastasis. [17] [18] [19] It has been well established that Tregs contribute to inhibition of the anti-tumour immune response. 20 The efficacy of many immunotherapeutic approaches that target T cell co-inhibitory and co-stimulatory receptors correlate with an altered balance in the ratio of effector T cells to Tregs in favour of the effector cells. 21 OVCAR3 that was pre-incubated with the blocking monoclonal antibodies also led to significant reduction of the in vitro invasion ability of OVCAR3. We concluded that expression changes of MMP-2 and TIMP-2 in ovarian cancer were closely associated with the levels of IL-10 and TGF-β1 secreted by CD4 + CD25 high CD127 low Tregs from EOC patients. On the basis of these findings, we believe that the invasion ability of EOC cells was at least regulated through the IL-10R and TGF-β1R signalling pathway. It was thought that the process by which CD4 + CD25 + CD127 low Tregs promoted tumour progression might involve some mechanisms. We considered that some indirect contact process played a particularly significant role for the Tregs-mediated invasion ability change of cancer cells. Our data proved that the high concentration of immunosuppressive cytokines in the tumour microenvironment, which was possibly secreted by CD4 + Tregs, may contribute to EOC cell metastasis and offer a new opportunity to develop effective therapeutics for intercepting tumour progression.
